Relapsed/Refractory Marginal Zone Lymphoma
![relapsed-refractory-marginal-zone-lymphoma-reacts-abivertinib](https://pharmtales.com/wp-content/uploads/2023/07/relapsed-refractory-marginal-zone-lymphoma-reacts-abivertinib.jpg)
Relapsed/Refractory Marginal Zone Lymphoma Reacts to Abivertinib
SG Tylor
A Phase IIa trial conducted in China demonstrated that treatment with the irreversible BTK inhibitor abivertinib (Fujovee) resulted in responses ...